GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 percent ...

The company plans to deliver exceptional new launches for driving innovation growth led by the adult shingles vaccine brand ...

GlaxoSmithKline Pharmaceuticals Limited reported that its revenue from operations in the second quarter of FY25 crossed Rs 1000 crore, up 5 per cent Year-on-Year. Profit After Tax (PAT) for the ...

Zobactin is ranked as the No. 2 brand (Dec MAT 2011 ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

For Shingrix, year-to-date growth was driven outside ... 14,000,15,000 people die every year in America. This is a brand-new vaccine with a cautious ACIP, but we are in their hands in terms ...

One of the clinic’s notable successes includes administering the "Shingrix" vaccine to organ transplant patients ... consecutive year and recognized as the most valuable healthcare brand in the ...

As a result, the company recently conducted an online study, alongside Kantar, a data analytics and brand consulting company ... A key product for the company is Shingrix (recombinant zoster ...